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FLICK: An optimized plate reader-based assay
to infer cell death kinetics
Evaluating drug sensitivity is improved by directly quantifying death kinetics, rather than
correlates of viability, such as metabolic activity. This is challenging, requiring time-lapse
microscopy and genetically encoded labels to distinguish live and dead cells. Here, we describe
fluorescence-based and lysis-dependent inference of cell death kinetics (FLICK). This method
requires only a standard fluorescence plate reader, retaining the high-throughput nature and
broad accessibility of common viability assays. However, FLICK specifically quantifies death,
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SUMMARY
Evaluating drug sensitivity is improved by directly quantifying death kinetics,
rather than correlates of viability, such as metabolic activity. This is challenging,
requiring time-lapse microscopy and genetically encoded labels to distinguish
live and dead cells. Here, we describe fluorescence-based and lysis-dependent
inference of cell death kinetics (FLICK). This method requires only a standard
fluorescence plate reader, retaining the high-throughput nature and broad
accessibility of common viability assays. However, FLICK specifically quantifies
death, including an accurate inference of death kinetics.
For complete details on the use and execution of this protocol, please refer to
Richards et al. (2020).
BEFORE YOU BEGIN
Calibrate the use of SYTOX for cells of interest
Timing: 1 day
1. In two 96-well, optical bottom, black-walled plates, add to the first column of both plates 40,000
cells in 180 mL of cell culture media (16 wells total). This first well will be used to generate a 2-fold
cell dilution across the plate. The final concentration for this first well will be 20,000 cells/well (i.e.,
20,000 cells per 90 mL).
Note: This protocol has been written for use with a Tecan Spark multimode plate reader, with
fluorescence readings taken from the bottom of the plate. Optical bottom plates are not
necessary if the plate reader used acquires fluorescence emission from the top of the wells.
However, even in this case, optical bottom plates may still be helpful for visualizing cell lysis
(see Before you begin, Step 8). Additionally, this protocol has been optimized for U2-OS cells.
Testing an altered range of cell densities may be optimal for other types of cells.
CRITICAL: Media containing phenol red has an insignificant effect on the SYTOX fluores-
cence signal or signal linearity. Other cell line-specific media reagents should be checked
for auto-fluorescence at 504/523 nm excitation and emission wavelengths.
2. Add 90 mL of media to all remaining wells in both plates (176 wells total).
3. Serially dilute cells 1:2 from the first column of the plates into the adjacent columns by removing
90 mL and adding it to the adjacent column to the right. Continue the dilution until reaching the
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11th column. The last column should not contain any cells on either plate and is used for deter-
mining background fluorescence signal.
a. Discard 90 mL from the 11th column wells.
Note: At this point all wells should have 90 mL of media. The first column should have 20,000
cells; the 11th column should have approximately 20 cells; the last column should contain only
media (Figure 1A).
4. Incubate plates at 37C and 5% CO2 for >4 h until the cells are adhered. Incubation time may be
longer or shorter depending on cell line of interest.
5. Prepare SYTOX reagent at 103 final concentration.
Figure 1. Optimizing SYTOX dyes for measuring cell death in a fluorescence plate reader
(A) Plating design for establishing a linear range and acquisition settings for SYTOX fluorescence. SYTOX dilution represented using green shades. Cell
dilution represented using blue shades.
(B) Visual inspection of cell permeabilization by Triton. Phase and SYTOX fluorescence images shown for cells exposed to 0.1% Triton-X. Images
collected using a 103 objective. Scale bar applies to all images, which are at the same magnification. Cell boundary for the highlighted cell was added
for illustrative purposes and is not part of the analysis. Inset image of the highlighted cell is a cropped 23 version of the same image.
(C) Optimal permeabilization times and degree of signal stability after cell lysis was determined by measuring SYTOX fluorescence at varied times after
cell permeabilization. Data are mean fluorescence in the well GSD, with data from 4 individual replicate wells overlayed.
(D) Establishing acquisition settings for SYTOX fluorescence. Linearity of SYTOX fluorescence evaluated at varied fluorescence gain settings (90–170).
SYTOX signal at a gain of 140 highlighted in black. Data are mean GSD of replicates following a 2 h Triton permeabilization with 5 mM SYTOX green,
using the plating design shown in (A).
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a. Prepare 103 SYTOX solutions in media at the following concentrations: 50, 40, 30, and 20 mM.
i. Add 10, 8, 6, or 4 mL of 5 mM SYTOX green to 1 mL of culturing media to create the 50, 40,
30, and 20 mM 103 stock solutions, respectively.
Note: SYTOX is used in this protocol to label dead cells. SYTOX fluorescence increases upon
binding to DNA, and fluorescence depends on loss of plasma membrane integrity. This gen-
eral mechanism is beneficial, as SYTOX can be used to evaluate the degree of cell death inde-
pendently from the mechanism of cell death. The FLICK method we describe for inferring
death kinetics can be used with any dye that labels dead cells independent of mechanism.
Other dyes that label dead cells in a death mechanism-specific manner (e.g., apoptotic spe-
cific) may be valuable for quantifying the kinetics of activation for specific death mechanisms.
6. Prepare 103 Triton-X permeabilization buffer.
a. Make a 103 Triton-X solution in cell culture grade PBS buffer by adding 50 mL Triton-X to 5 mL
PBS (1.0% solution). Mix the solution by inverting the tube. Avoid shaking.
Note: To help dissolve Triton-X, the solution can be put in a 37C water bath for 5 min. The
final concentration of Triton-X when added to cells can be between 0.05%–0.15%. The 103
solution should adjusted accordingly if using a final concentration other than 0.1%.
7. Add 103 SYTOX solutions (Figure 1A).
a. Each 103 SYTOX solution will be added to 4 rows of cells creating quadruplicate measure-
ments for each dilution (Figure 1A).
i. To the first 4 rows on plate 1, add 10 mL of 50 mM103 SYTOX solution from step 5 for a final
concentration of 5 mM.
ii. To the last 4 rows on plate 1, add 10 mL of 40 mM 103 SYTOX solution from step 5 for a final
concentration of 4 mM.
iii. To the first 4 rows on plate 2, add 10 mL of 30 mM103 SYTOX solution from step 5 for a final
concentration of 3 mM.
iv. To the last 4 rows on plate 2, add 10 mL of 20 mM 103 SYTOX solution from step 5 for a final
concentration of 2 mM.
Note: These data will be used to optimize the concentration of SYTOX and the fluorescence
acquisition settings on the plate reader. The technical replicates are not intended to capture
other sources of biological or experimental variation. See Optimizing Experimental Design,
step 14 for details on optimizing plating designs.
8. Permeabilize cells (Figures 1B and 1C).
a. Add 10 mL of 1% Triton-X solution prepared in step 6 to all wells for a final concentration of
0.1%.
b. Place plates in incubator at 37C and 5% CO2 for approximately 1.5–2 h to allow for cell per-
meabilization.
CRITICAL: The timing for permeabilization will vary depending on cell line and Triton-X
concentration. It may be necessary to incubate longer to ensure complete cell lysis. Check
for cell permeabilization under a microscope (Figure 1B). Following lysis, cell morphology
should be significantly altered. No discernable intact cells should remain in the well, with
only cell debris remaining (see Figure 1B, 2 h). A key observation is the change in nuclear
morphology and lack of clear nuclear boundary (see Figure 1B, change between 1 and 2 h).
Even following dramatic changes to nuclear morphology, total well fluorescence is largely
unaffected (Figure 1C). If fluorescence and/or phase microscopy is not available, perme-
abilization time can be optimized by reading the plate over time, to determine when
the signal hits a stable plateau.
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9. Set up the plate reader for quantification of SYTOX fluorescence.
a. The excitation and emission wavelengths should be set to 504/523 nm with a bandwidth of
5 nm, if possible.
b. Flash number should be set at 5.
Note: The settings above are specified for the Tecan Spark. Settings will vary based on the
plate reader. Some models may allow control of fluorescence integration time rather than
flash number. Integration time should be kept short to minimize photobleaching.
CRITICAL: Once cells are lysed, the SYTOX signal is stable (Figure 1C). Avoid shaking or
agitating the plate at this step, which can result in dislodging/aggregation of the cells,
leading to inaccurate readings in some plate readers (Grootjans et al., 2016).
10. Collect SYTOX fluorescence using range of gain settings (Figure 1D).
a. For each of the four SYTOX concentrations, collect fluorescence data using a spectrum of
gain values. Gain settings should include levels that produce low signals at all cell numbers,
through gain settings that produce saturated fluorescence signals in wells containing high
cell numbers. Saturated signals are reported as ‘‘invalid’’ (INV) or ‘‘NaN’’ in most plate
readers, and refer to signals that are above the maximum detectable limit (65,000 fluores-
cence units for the Tecan Spark). Refer to the plate reader manual to determine the maximum
fluorescence signal that can be detected.
11. Data analysis to determine optimal acquisition settings.
a. Remove the background fluorescence from each measurement by calculating the mean
signal from wells that do not contain cells; subtract this mean value from the signal for all
wells.
b. For each SYTOX concentration and gain condition, compare the background subtracted
fluorescence signal to the cell number (Figure 1D).
c. Determine the correlation coefficient (R2) for each condition using linear regression.
i. In MATLAB, the built-in function ‘‘corrcoef’’ can be used to compute the Pearson correla-
tion coefficient (R).
ii. In Excel, correlation coefficient can be calculated using the function ‘‘CORREL.’’
d. Select the SYTOX concentration and gain setting that gives the best combination of linearity
and dynamic range.
i. The maximum signal (wells that contain 20,000 cells) should be less than 80%–90% of the
detection limit (65,000 relative fluorescence units on the Tecan Spark).
ii. In most titration experiments a range of gain values produce large dynamic range and R2 >
0.99 (Figure 1D, gain values between 120–140 are all acceptable). See Table 1 for
example settings used for other cell lines.
Table 1. Example SYTOX calibration settings (all using 5mM SYTOX green)


















12. Option 1 – Set up a T0 control plate to determine live and dead cell numbers at assay start.
a. When designing an experiment to calculate lethal fraction over time, a T0 control plate
should be used to estimate the initial lethal fraction, the proportion of cells that are alive
versus dead, at the start of the assay. This plate is seeded at the same time as experimental
plates with the same number of cells, but will be lysed at the start of the experiment. An entire
96 well plate should be used for this calculation (see Quantification and statistical analysis
step 2).
13. Option 2 – Estimate the live and dead cells at assay start from previous experiments.
a. Fluorescence readings from a previous experiment can be used as an approximation to
determine the initial cell counts if the same number of cells were seeded in both experiments.
CRITICAL: Do not lyse a subset of wells on an experimental plate as the T0 control. The
lysis buffer can permeate to other wells across the plate over time, causing lysis.
14. Consider the optimal plating layout (Figures 2A and 2B).
a. Evaporation and slow growth often occur on the outer edges of the plate. We have observed
that drug-induced lethal fraction is not generally altered by growth rate. Additionally,
because lethal fraction is internally controlled (i.e., does not require comparison between
two wells), the outer edges can be used if downstream analyses focus exclusively on lethal
fraction. However, one should expect lower total cell counts in these wells. Relative viability,
which requires comparison between separate wells on a plate should not be calculated using
the edge wells (Figure 2C).
b. Other sources of variability in this assay could include inconsistencies in cell plating between
plates or on separate days. Additionally, variations in Triton permeabilization efficiency may
Figure 2. Optimal plating designs for analysis of drug sensitivity using common pharmacometrics
(A and B) Schematics of 96-well plating layouts containing drugs at varied doses (graded colors), vehicle controls (gray), and untreated wells (white). (A)
Edge wells are often omitted due to different growth characteristics. Vehicle controls arrayed systematically across the plate can assist with identifying/
normalizing plating biases if needed. This standard design has no technical replicates and biological replicates located on separate plates. (B) Partial
use of edge wells, with high doses of drug on one edge, and vehicle controls across top edge and two columns of the plate. Using this design,
normalization to vehicle controls should be performed using the plate mean across all vehicle wells to minimize edge effects.
(C) Variable influence of plating design, dependent on choice of downstream analysis metrics. Data shown for relative viability (RV or RV edge; defined
as live cells in treated wells compared to control) or Fractional Viability (FV or FV edge; defined as live cells in each well compared to total of live and
dead cells in the same well). Data are for DMSO treated wells using a plating design, similar to (A). For RV, DMSO treated wells were normalized relative
to the plate average for all DMSO treated wells. For RV edge, DMSO treated wells were normalized relative to the average of all untreated wells, which
were located on the plate edge. FV refers to the fraction of live cells in DMSO treated wells. FV edge refers to the fraction of live cells in edge wells. Use
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exist for plates that are lysed at different times or from different permeabilization buffers. The
plating design should avoid confounding theses sources of variation with treatment groups.
Note: The T0 control plate can be used to correct for the growth variability if necessary. This
should only be done if users have validated that a systematic plating location bias reproduc-
ibly occurs on a given plate reader.
15. Delivering compound and SYTOX reagent.
c. When possible, 103 compound stocks should be made in media containing 103 SYTOX.
This allows the operator to dispense both reagents into the well in a single pipette stroke.
The cell plating volume should be adjusted so a final volume of 100 mL in the well is achieved,
after adding SYTOX and compound.
Note: 100 mL final volume is used in order to limit the amount of reagents needed, and
because U2-OS cells grow at expected rates when plated at these densities in this volume.
Plating volumes can be adjusted if needed, based on the growth characteristics of the cells
in the study.
CRITICAL: At high concentrations of drug, the percentage of DMSO may be above the
tolerance of cells. It is important to have vehicle controls on the plate to determine the
contribution of death from DMSO.
KEY RESOURCES TABLE
MATERIALS AND EQUIPMENT
Alternatives: This protocol uses a Tecan Spark Multimode plate reader. Essentially any other
plate reader should also be suitable. The minimal requirement is only the ability to quantify a
REAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, peptides, and recombinant proteins
SYTOX green Thermo Fisher Scientific Cat# S7020
Triton Fisher BioReagents Cat# BP151-500




fitGrowth function Richards et al., 2020 https://github.com/MJLee-Lab/fitGrowth
fitLED function Richards et al., 2020 https://github.com/MJLee-Lab/fitLED
fit_via function Richards et al., 2020 https://github.com/MJLee-Lab/fit_via




fitGrowth function Richards et al., 2020 https://github.com/MJLee-Lab/fitGrowth
fitLED function Richards et al., 2020 https://github.com/MJLee-Lab/fitLED
fit_via function Richards et al., 2020 https://github.com/MJLee-Lab/fit_via
PRISM GraphPad Version 9.0.0
Excel Microsoft Excel for Mac version 16.42
Other
Microplate fluorescence reader Tecan Spark
Optical bottom black-walled 96 well plates Greiner Bio-One 655090
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single channel of fluorescence associated with labeling of dead cells. Labeling of dead cells in
this protocol is performed using the SYTOX green dye. SYTOX dyes in other colors are also
suitable, assuming these can be read in the chosen plate reader. SYTOX dyes are used in
this protocol as their fluorescence is increased when bound to DNA in dead cells, and these
dyes are not toxic to live cells, enabling kinetic analysis. Other dyes with these features should




Following experimental design, cells should be grown and collected to be plated into 96 well, op-
tical bottom, black-walled plates. The number of plates needed is dictated by the number of condi-
tions to be tested; however, an additional T0 control platemust also be plated. Care should be taken
in accurately counting and seeding cells. This will reduce noise in the fluorescence measurements
and provide consistent data between replicates. Two technical replicates are performed on the
same plate to account for plating bias. Additionally, biological replicates should also be performed
on separate plates or experiments performed on subsequent days.
1. Cell line of interest should be cultured according to established protocols.
Note: This protocol is suitable for cells with any growth morphologies or characteristics. Very
small cells or cells that grow with uneven density (clumpy or in colonies) will generate noisier
data, particularly at low cell densities. This may compromise the low end sensitivity of the
assay.
2. Count cells using a hemocytometer or automatic cell counter.
3. Dilute cells to the appropriate concentration in cell culture media that allows for the proper seed-
ing density. Cells should be seeded at a starting density at which untreated cells do not become
confluent during the assay, taking into account the doubling time, well size, and length of the
experiment. Following counting, cells should be resuspended at a concentration that allows
for plating at 90 mL/well.
4. Resuspend cells by gently pipetting up and down, then add 90 mL of cell suspension to plates.
a. See step 14 in Before you begin and Figure 2 for optimal experimental designs, including num-
ber of technical and/or biological replicates per experiment.
5. Place in incubator at 37C and 5% CO2 to adhere overnight (4–18 h).
Pause point: The assay can begin immediately after the cells have adhered to the plate.
Most commonly, drugs are added the following morning after plating, but the assay could
also start anytime within the following 2–3 days while the wells are not confluent and the cells
are growing normally. Whatever decision is made should be consistent across all plates in a
given experiment.
Adding SYTOX and compound
Timing: 1 h
SYTOX green solutions with and without compound are prepared and added to experimental wells.
A 1% Triton-X solution is prepared and added to the T0 control plate to determine initial total cell
fluorescence.
6. Prepare a 1% Triton-X permeabilization buffer in sterile PBS.
ll
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a. Approximately 1 mL is required to permeabilize an entire 96-well plate. Extra should be made
to account for dead volume, particularly if dispensed from a reservoir using a multi-channel
pipette.
7. Prepare a 103 SYTOX solution (see Before you begin step 11) by diluting 5 mM SYTOX in enough
volume of culture media for your experimental design. The total volume should be enough for all
dilutions, experimental wells, and T0 control plate.
8. Dilute the compounds of interest to 103 the final desired concentration in 103 SYTOX solution.
This should also be done for a vehicle control. If doing dose-response experiments, it is recom-
mended to create 103 drug dilutions in round-bottom plates by serial dilution.
Note: Round-bottom plates are recommended to reduce the dead volume during pipetting
9. Add 10 mL of the SYTOX+compound (or vehicle) solution to appropriate wells. Add 10 mL of 103
SYTOX only solution to the T0 control plate. The final volume of the well should now be 100 mL
with 13 SYTOX and 13 compound (or vehicle).
10. Add 10 mL of 1% Triton-X permeabilization buffer to all wells of the T0 plate and place in the




This step quantifies the raw fluorescence of dead cells at chosen time points. After the final measure-
ment is taken, cells are lysed using Triton-X buffer to quantify the total cell fluorescence at the end of
the assay.
11. Set the fluorescence plate reader to the appropriate excitation, emission, and gain settings for
the chosen SYTOX concentration.
12. Take an initial reading for the experimental plates. Once the measurement is finished, keep the
plate stored in the incubator at 37C and 5% CO2 until the next time point.
13. Once the T0 control plate is fully permeabilized (step 10), measure the fluorescence. This mea-
surement of Total Starting Fluorescence will be used later in Quantification and statistical anal-
ysis, step 2. Discard the plate when finished.
14. Continue taking measurements at selected time points until the end of the experiment.
a. Common assay lengths are generally 48–72 h after drug addition, but these depend on the
growth rate of cells being tested.
b. Time points should be  4 h apart, at a roughly constant interval, and selected to capture
multiple (2–3) time points within the increasing phase of the response and the plateau
phase of the response. Selected time points should be the same across biological repli-
cates.
Note: Both the frequency and the interval of measurements will affect the accuracy of the ki-
netic fitting (Quantification and statistical analysis, step 3). In particular, the inference of death
onset time (DO) depends on capturing changes in cell death within both the increasing phase
and plateau phase of the response. See Troubleshooting for more details. Plates should
remain in the incubator between time point measurements unless the plate reader used is
equipped with a temperature and CO2 controlled environmental chamber. Temperature fluc-
tuations caused by frequent removal from the incubator may compromise cell health and/or
growth rate.
15. Prior to reading the final time point, prepare fresh 1% Triton-X permeabilization buffer. Prepare
enough volume to lyse all experimental wells.
ll
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16. After the final measurement, add 10 mL of 1% permeabilization buffer to each well. Lyse the plate
for > 2 h at 37C and 5% CO2
a. Once all wells have been fully lysed, take a final fluorescence measurement. This final mea-
surement is proportional to the total cell count at the end of the assay.
CRITICAL: Before taking the total cell count measurement, check the plate for complete
lysis under a microscope. See Before you begin, step 8, and Figures 1B and 1C for more
details.
EXPECTED OUTCOMES
The FLICK method is designed to provide a specific measurement of cell death, rather than an indi-
rect surrogate of cell viability. Other assays that are specific to cell death generally use time-lapse
microscopy to track live and dead cells over time. In the FLICK method, this is achieved by direct
measurement of the dead cell population over time, and a computational inference of the live cell
population. Additionally, because FLICK does not require the use of any genetically encoded labels,
this method can be used more flexibly, to quantify responses in diverse settings, including for pri-
mary cells.
The outlined procedure will generate temporally resolved fluorescence data that is proportional to
the number of dead cells contained within a well (Figure 3A). Additionally, this protocol generates an
experimentally determined measurement that is proportional to the total number of cells (e.g., live
and dead) at the start and end of the assay. Total cell fluorescence at intermediate time points (i.e.,
any time point between the beginning and end of the assay) is computationally inferred using the
experimentally observed cell fluorescence at the start and end of the assay as constraints (see Quan-
tification and statistical analysis, Figure 3B). For all wells, fluorescence following endpoint permea-
bilization should be equal to- or higher than the T0 fluorescence (Figures 4A and 4B, see Trouble-
shooting section for additional details). For vehicle-treated wells, fluorescence measurements
after endpoint permeabilization should be substantially higher than measurements taken at the
end point of the assay prior to permeabilization, reflecting an expected low percentage of dead cells
in the population (Figures 4B and 4C). Outcomes for drug-treated wells will vary depending on the
concentration and mechanism of action (death, growth arrest, or a combination of death and arrest)
Figure 3. Overview of the FLICK assay
(A) Schematic of steps for data collection using FLICK.
(B) Schematic of steps for analysis of data generated using FLICK.
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(Schwartz et al., 2020). Death-inducing drugs should cause an increase in the fluorescence signal
over time and may plateau at later time points. Alternatively, drugs that primarily induce growth ar-
rest may not cause an increase in SYTOX fluorescence, but a noticeable decrease in the total cell
fluorescence after permeabilization should be observed.
Drug-induced cell death can be observed directly from the SYTOX fluorescent signal, which is pro-
portional to the number of dead cells; however, this signal alone should not be used to evaluate drug
response, due to the lack of insight about population size (Forcina et al., 2017). The peculiar concen-
tration dependence of SGI-1027 provides an example of unreliable insights derived from counting
dead cells alone, when population size is not also considered. SGI-1027 is a DNAmethyl-transferase
inhibitor which leads to both growth arrest and cell death, but with varied timing and varied intensity,
depending on the dose used. At low concentrations (1 mM), SGI-1027 causes low levels of cell death
(Figure 4A). At these low concentrations, however, the total cell count at the end of the experiment is
reduced compared to the vehicle control, revealing a modest anti-proliferative effect at this concen-
tration (Figures 4B and 4C). At higher concentrations (3.16 and 31.6 mM), all cells are killed by the end
of the assay; however, the data do not follow an expected dose-dependent response. Instead, SGI-
1027 at 3.16 mM kills a larger total number of cells than at a higher dose of 31.6 mM (Figure 4A). This
discrepancy is caused by the fact that exposure to 31.6 mM SGI-1027 results in a very fast onset time
of death (DO) and rate of death (DR), essentially killing all plated cells before any cell division can
Figure 4. Kinetic analysis of drug response using the FLICK assay
Analysis of response to SGI-1027 at varied doses. Due to varied rates of death onset, SGI-1027 results in cell death that appears to peak at intermediate
doses.
(A) Quantification of dead cell fluorescence over time.
(B) Quantification of live cell fluorescence at assay endpoint. The live cell fluorescence corresponds to the difference between the SYTOX fluorescence
pre-Triton permeabilization (PRE) and post-Triton (POST) permeabilization.
(C) Population size at any intermediate time point is estimated based on the experimentally observed population size at the beginning and end of the
assay.
(D) Lethal fraction (LF) kinetics for SGI-1027. Unlike dead cell fluorescence, LF reveals dose-dependent increase in drug efficacy.
(E and F) Kinetic parameters from the LED analysis. (E) Death onset time (DO) at each tested dose of SGI-1027. Camptothecin shown for comparison. (F)
Death rate (DR) at each tested dose of SGI-1027. Camptothecin shown for comparison. For (A) and (D)–(F), data are mean G SD of 4 biological replicates.
For (F) and (G), dose ranges tested were half-log dilutions starting at 31.6 mM. If death was not significantly above baseline values at the assay endpoint,
rates were not calculated (n.a., not applicable).
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occur. Computing the drug-induced lethal fraction – which considers both the number of dead cells
and the population size – reveals a more reliable insight about the drug response, including the
dose-dependent variation in death onset time (Figures 4D–4F). Additionally, lethal fraction or its in-
verse, fractional viability, also reveals a more typical dose-dependent increase in cell death (Fig-
ure 4D, 5A, and 5B).
Lethal fraction or fractional viability produce reliable insights regarding the degree of drug-induced
cell killing. However, these measures do not capture drug-induced changes in the population size.
Alternatively, relative viability, the most commonly used measurement for evaluating drug sensi-
tivity, ignores the degree of cell killing, instead reporting only changes in population size (Figures
5A and C). Importantly, because this protocol facilitates quantification of both live and dead cells,
these methods can be used to quantify any commonly used drug response metric, including relative
viability or the normalized growth rate inhibition value (GR) (Figures 5A and 5D). Drugs vary in the
degree to which they activate cell death versus inhibit growth (Schwartz et al., 2020). For drugs
like SGI-1027, that primarily activate death without strongly inhibiting cell proliferation, FV, RV,
and GR metrics will produce very similar insights (Figures 4B–4D). Alternatively, other drugs like
camptothecin activate cell death at high doses, but also strongly inhibit cell proliferation, even at
low doses. For these drugs, FV, RV, and GR metrics tend to produce different insights (Figures
4B–4D). Each of these metrics can be appropriate, depending on the focus of a study, but each
metric produces unique and incomplete insights. Additionally, using data generated from this pro-
tocol, the complementary insights derived from cell death-focused or population size-focused
Figure 5. Pharmacological analyses of drug response
Comparison of common pharmaco-metrics.
(A) Definitions for fractional viability (FV), relative viability (RV), and normalized growth rate inhibition (GR). FV is the fraction of a cell population that is
alive. RV is the size of the drug-treated cell population, compared to the vehicle control population. GR is the relative population growth rate of drug-
treated cells, compared to control.
(B–D) Sample data for response to SGI-1027 (top) or Camptothecin (bottom) in U2-OS cells. (B) FV. (C) RV (D) GR. For each panel in (B)–(D), the IC50, or
equivalent, is shown. IC50 refers to the dose associated with 50% reduction from the starting value. Curve fitting generates the EC50 parameter, which
refers to the dose of the observed half-maximal response. Data are mean G SD of biological replicates.
ll
OPEN ACCESS
STAR Protocols 2, 100327, March 19, 2021 11
Protocol
pharmacometrics can be integrated by calculating drug GRADE (Schwartz et al., 2020). GRADE anal-
ysis reveals the degree of drug-induced cell death versus drug-induced proliferative arrest induced
by a given drug. Other common assays generate signals proportional tometabolic activity (CellTiter-
Glo, MTT, Alomar Blue). Unlike FLICK, these other assays do not provide specific information on the
degree of drug-induced cell death, and can only be used to score relative viability.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantify the fluorescence associated with dead and live cells over time
1. Determine the SYTOX fluorescence of dead cells (FDt) at each time point for each condition (Fig-
ure 4A)
a. SYTOX fluorescence is proportional to the number of dead cells and should be measured
immediately after the assay start, followed by measurements at any additional timepoints (t)
of interest (Table 2).
2. Model the population growth over time (Figures 4B and 4C).
a. After the last time point has been taken, determine the SYTOX fluorescence of total cells (FT)
at the end of the experiment by measuring the fluorescence following permeabilization with
Triton (Figure 4B and Table 3, FT48).
Note: Fluorescence values following Triton permeabilization are proportional to the total
number of cells (live + dead).
b. Determine the SYTOX fluorescence following Triton permeabilization for the T0 Control plate
(FT0).
i. An average starting value (FTM0) should be determined by calculating the 50% trimmed
mean from the fluorescence of permeabilized cells (Table 4). The trimmed mean refers to
the mean of the data, following removal of the highest and lowest outliers.
 In MATLAB, use the built-in function ‘‘trimmean’’ (i.e., trimmean(x,50)).
 In Excel or similar, sort the T0 data and remove the top and bottom 25%. Compute the
mean of the remaining 50%.
Note: Computing an average starting fluorescence value is done here for robustness, as well-
to-well variations are likely to fluctuate from plate to plate. Computing this average from a
Table 2. Fluorescence of dead cells (FDt)
Camptothecin dose (mM) Replicate #
SYTOX fluorescence (relative fluor. units, RFU)
FD0 FD16 FD20 FD24 FD40 FD44 FD48
0 1 234 236 251 247 325 332 354
0.01 1 239 273 264 269 341 349 405
0.0316 1 253 252 258 267 335 346 351
0.1 1 224 253 259 261 387 445 388
0.316 1 238 265 277 299 407 471 501
1 1 242 371 593 856 1,058 1,222 1,364
3.16 1 257 647 1,324 1,765 2,630 3,169 3,630
10 1 239 502 1,142 1,862 3,201 3,457 3,820
0 2 226 236 253 258 347 385 439
0.01 2 230 279 246 257 344 388 429
0.0316 2 246 254 251 266 347 361 389
0.1 2 221 232 245 253 304 340 358
0.316 2 267 268 282 282 392 550 515
1 2 250 352 567 776 1,128 1,393 1,674
3.16 2 238 600 1,255 1,688 2,659 3,253 3,819
10 2 262 604 1,317 2,154 3,308 3,836 4,131
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trimmed portion of the data may reduce the influence of single outlier wells that may exist for
technical reasons (incomplete lysis, error in plating, etc.). A similar method is used in other
studies (Hafner et al., 2016).
c. For each condition, fit the starting (FTM0) and final (FT48) total cell fluorescence values to an
exponential curve:
FTðtÞ = aeðktÞ
t = time point
k = growth rate per hour
a = initial starting population
i. In MATLAB, this can be performed using the built-in function ‘‘fit’’ and the fit type ‘‘exp1.’’
ii. In PRISM, this can be performed using the nonlinear regression curve fitting package, with
the exponential growth equation.
iii. In excel, this can be performed by generating a signal vs. time scatter plot, and adding an
exponential trendline
d. Estimate the total fluorescence at each intermediate time point (FTt) by solving the above
equation at all desired time points (t), once the a and k parameters have been solved from
the curve fitting (Figure 4C and Table 5).
Note: This estimate is based on the assumption of exponential population growth at uniform
rate. Population growth over time in the absence of drug is likely to be approximately expo-
nential. In the presence of drug, the population growth dynamics may not be exponential and
may not be uniform over time. Our simulations demonstrate that the accuracy of lethal fraction
kinetics do not depend on the validity of this assumption, as lethal fraction kinetics computed
using this method were similar under many different assumed growth models. Additionally,
lethal fraction kinetics computed using this method were similar to those experimentally
Table 3. Total cell fluorescence at assay endpoint (FT48)
Camptothecin dose (mM) Rep. #
SYTOX fluorescence of total cells (RFU)
FTM0 FT16 FT20 FT24 FT40 FT44 FT48
0 1 – – – – – – 14,747
0.01 1 – – – – – – 14,713
0.0316 1 – – – – – – 12,829
0.1 1 – – – – – – 8,507
0.316 1 – – – – – – 6,411
1 1 – – – – – – 6,828
3.16 1 – – – – – – 4,376
10 1 – – – – – – 4,809
0 2 – – – – – – 17,605
0.01 2 – – – – – – 15,027
0.0316 2 – – – – – – 11,393
0.1 2 – – – – – – 7,935
0.316 2 – – – – – – 6,011
1 2 – – – – – – 6,648
3.16 2 – – – – – – 4,462
10 2 – – – – – – 4,636
Table 4. Fluorescence of total population at assay start (FT0)
SYTOX fluorescence of total population at T0 (RFU)
FT0 3,197 3,470 3,475 3,685 3,700 3,883 3,927 3,988
. . . . . . . .
3,994 4,316 4,320 4,519 5,021 5,814 6,359 6,477
50% trimmed mean (FTM0) 4,081
ll
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calculated from time-lapse microscopy. This robustness depends on the length of the assay,
as in short-term assays (48–72 h; effectively 2–3 population doublings), many different growth
models produce a similar inference of live cell numbers or death kinetics. For longer assays,
other growth models may provide more accurate estimates, including growth models with
non-uniform rates over time (Richards, et al. 2020). See comment in Limitations below.
e. Subtract the measured fluorescence of dead cells (Table 2) from the total cell fluorescence
generated in Table 5. The remaining fluorescence is proportional to the size of the live pop-
ulation at each time point (Table 6).
FLðtÞx = FTt;x  FDt;x
FT = fluorescence of total cells (Table 5)
FD = fluorescence of dead cells (Table 2)
t = a given timepoint
x = a given drug concentration
Note: This simple subtraction (fluorescence of the total population – fluorescence of the dead
population) should be proportional to the number of live cells. The accuracy of this inference
depends on the linearity of the SYTOX fluorescence signal with cell number (Before you begin,
steps 10 and 11, Figure 1D).
Calculate lethal fraction (LF) kinetics
3. Calculate lethal fraction kinetics (Figure 4D).




FD = dead cell fluorescence (from Table 2)
FL = live cell fluorescence (from Table 6)
t = a given time point
x = a given drug concentration
b. For each dose of drug, determine response kinetics using a Lag Exponential Death (LED)
equation (Forcina et al., 2017) (Table 8):
LFðtÞ = LFi +

LFp  LF0
  1 eDR ðtDO Þ
Table 5. Fluorescence of the total population (FTt)
Camptothecin dose (mM) Rep. #
SYTOX fluorescence of the total population (RFU)
FTM0 FT16 FT20 FT24 FT40 FT44 FT48
0 1 4,081 6,262 6,970 7,758 11,905 13,250 14,747
0.01 1 4,081 6,258 6,963 7,749 11,882 13,222 14,713
0.0316 1 4,081 5,978 6,577 7,236 10,600 11,661 12,829
0.1 1 4,081 5,213 5,542 5,892 7,527 8,002 8,507
0.316 1 4,081 4,744 4,926 5,115 5,946 6,174 6,411
1 1 4,081 4,845 5,057 5,279 6,267 6,541 6,828
3.16 1 4,081 4,177 4,201 4,226 4,325 4,351 4,376
10 1 4,081 4,310 4,370 4,430 4,679 4,744 4,809
0 2 4,081 6,643 7,504 8,476 13,798 15,586 17,605
0.01 2 4,081 6,302 7,025 7,831 12,093 13,480 15,027
0.0316 2 4,081 5,746 6,259 6,819 9,601 10,459 11,393
0.1 2 4,081 5,094 5,384 5,690 7,103 7,507 7,935
0.316 2 4,081 4,643 4,795 4,953 5,635 5,820 6,011
1 2 4,081 4,802 5,001 5,209 6,129 6,383 6,648
3.16 2 4,081 4,204 4,236 4,267 4,396 4,429 4,462
10 2 4,081 4,258 4,304 4,350 4,538 4,587 4,636
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LFi = initial lethal fraction prior to death onset, unconstrained
LFp = lethal fraction plateau, constrained by LFp < 1
DO = onset time of death, constrained by 0 < DO < final timepoint
DR = maximum rate of death, constrained by DR < 2
The four kinetic parameters of the LEDmodel should be determined using a least squares regression
based curve fitting.
i. In MATLAB, this can be performed using the built-in function ‘‘fit.’’ See associated GitHub
repository to access a custom built function.
ii. In PRISM, LED parameters can be solved using the ‘‘plateau followed by one-phase asso-
ciation’’ function in the nonlinear regression, exponential analysis package, with manually
constrained death onset time (X0 in PRISM).
Note: the LED equation is useful for determining the kinetics of cell death, namely through the
DO and DR parameters. These features are not observable from end point data, and differ
across drugs and drug classes (Inde et al., 2020). SGI-1027 has a dose-dependent decrease
in DO whereas Camptothecin has more stable DO across doses (Figure 4E). Both SGI-1027
and Camptothecin result in near complete cell killing at high doses, but the death occurs at
very different rates (Figure 4F).
c. For drugs/doses that do not induce significant levels of cell death (see Table 8, *), kinetic terms
are unreliable. These data are instead fit to a linear model with slope = 0 (Table 9):
LFðtÞ = 0ðtÞ+ LFi
LFi = initial lethal fraction prior to death onset, unconstrained
i. Lack of drug-induced cell death can be determined based on the error among replicates
(i.e., no significant change from LFi over the time course). Alternatively, non-killing drugs
can be defined as those for which LFmax values are not 23 greater than LFi.
ii. In MATLAB, curve fitting can be performed using the built-in function ‘‘fit,’’ defining the fit-
type as ‘‘poly1.’’
iii. In PRISM or Excel, data can be fit using linear regression.
Table 6. Fluorescence of live cells (FLt)
Camptothecin dose (mM) Rep. #
SYTOX fluorescence of live cells (RFU)
FL0 FL16 FL20 FL24 FL40 FL44 FL48
0 1 3,847 6,026 6,719 7,511 11,580 12,918 14,393
0.01 1 3,842 5,985 6,699 7,480 11,541 12,873 14,308
0.0316 1 3,828 5,726 6,319 6,969 10,265 11,315 12,478
0.1 1 3,857 4,960 5,283 5,631 7,140 7,557 8,119
0.316 1 3,843 4,479 4,649 4,816 5,539 5,703 5,910
1 1 3,839 4,474 4,464 4,423 5,209 5,319 5,464
3.16 1 3,824 3,530 2,877 2,461 1,695 1,182 746
10 1 3,842 3,808 3,228 2,568 1,478 1,287 989
0 2 3,855 6,407 7,251 8,218 13,451 15,201 17,166
0.01 2 3,851 6,023 6,779 7,574 11,749 13,092 14,598
0.0316 2 3,835 5,492 6,008 6,553 9,254 10,098 11,004
0.1 2 3,860 4,862 5,139 5,437 6,799 7,167 7,577
0.316 2 3,814 4,375 4,513 4,671 5,243 5,270 5,496
1 2 3,831 4,450 4,434 4,433 5,001 4,990 4,974
3.16 2 3,843 3,604 2,981 2,579 1,737 1,176 643
10 2 3,819 3,654 2,987 2,196 1,230 751 505
ll
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Calculate pharmacological dose-responses using fractional viability (FV), relative viability
(RV), or normalized growth rate adjusted values (GR)
4. Calculate fractional viability (FV, Figures 5A and 5B)
Note: FV is a commonmeasure of drug response for assays that count both live and dead cells
(flow cytometry, quantitative microscopy, etc.). Unlike RV, FV does not report changes in pop-
ulation size, but rather the proportion of the population that is alive or dead. FV is the inverse
of LF (FV = 1  LF).
a. Calculate fractional viability (FV) for each condition/timepoint (Table 10):
FVðtÞx = 1 LFt;x
LF = lethal fraction (from Table 6)
t = a given time point
x = a given drug concentration
b. Determine pharmacological parameters for FV values by curve fitting, using the same 4-
parameter logistic regression as for RV, above inQuantification and statistical analysis step 4b.
5. Calculate relative viability (RV, Figures 5A and 5C).
Note: RV is a commonmeasure of drug response used for most assays that rely onmeasures of
metabolic activity (CellTiter-Glo, MTT, Alamar Blue, etc.). This measure reports the drug-
induced change in population size, compared to untreated or vehicle-treated populations.
a. Calculate relative viability (RV) for each condition/timepoint (Table 11).




FL = modeled live cell fluorescence (from Table 6)
t = a given time point
x = a given drug concentration
b. Model RV values using a 4-parameter logistic regression (at any timepoint but most commonly
using data from the assay endpoint):
Table 7. Lethal fraction (LFt)
Camptothecin dose (mM) Rep. #
Lethal fraction
LF0 LF16 LF20 LF24 LF40 LF44 LF48
0 1 0.0573 0.0377 0.0360 0.0318 0.0273 0.0251 0.0240
0.01 1 0.0586 0.0436 0.0379 0.0347 0.0287 0.0264 0.0275
0.0316 1 0.0620 0.0422 0.0392 0.0369 0.0316 0.0297 0.0274
0.1 1 0.0549 0.0485 0.0467 0.0443 0.0514 0.0556 0.0456
0.316 1 0.0583 0.0559 0.0562 0.0585 0.0684 0.0763 0.0781
1 1 0.0593 0.0766 0.1173 0.1622 0.1688 0.1868 0.1998
3.16 1 0.0630 0.1549 0.3151 0.4177 0.6080 0.7284 0.8295
10 1 0.0586 0.1165 0.2613 0.4203 0.6841 0.7288 0.7943
0 2 0.0554 0.0355 0.0337 0.0304 0.0251 0.0247 0.0249
0.01 2 0.0564 0.0443 0.0350 0.0328 0.0284 0.0288 0.0285
0.0316 2 0.0603 0.0442 0.0401 0.0390 0.0361 0.0345 0.0341
0.1 2 0.0542 0.0455 0.0455 0.0445 0.0428 0.0453 0.0451
0.316 2 0.0654 0.0577 0.0588 0.0569 0.0696 0.0945 0.0857
1 2 0.0613 0.0733 0.1134 0.1490 0.1841 0.2182 0.2518
3.16 2 0.0583 0.1427 0.2963 0.3956 0.6049 0.7345 0.8559
10 2 0.0642 0.1418 0.3060 0.4952 0.7289 0.8363 0.8911
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RVðxÞ = Emax + RV0  Emax1+ 10ððxEC50Þ3 hillÞ
x = dose in log10 scale
Emax = maximum effect (e.g., bottom of curve)
RV0 = relative viability in absence of drug (e.g., top of curve)
EC50 = dose in log scale corresponding to the mid-point of the sigmoidal curve (inflection point)
h = Hill coefficient
The four parameters of the logistic regression model should be determined using a least squares
regression based curve fitting.
i. In MATLAB, this can be performed using the built-in function ‘‘fit,’’ defining the fit type us-
ing the equation listed above. See associated GitHub repository to access a custom built
function.
ii. In PRISM, this can be performed using the ‘‘log(inhibitor) vs. response – variable slope’’
analysis function.
Note: This equation requires a log-transformation of the dose values and cannot accept a
dose of ‘‘0.’’ These doses can be omitted from the fit or set to a value 103 lower than the
lowest dose.
6. Calculate the normalized growth rate inhibition value (GR, Figures 5A and 5D).
Note: GR reports the drug response in terms of the growth rate of drug-treated cells,
compared to the untreated growth rate. This approach normalizes for differences in the
apparent drug response that may be due to differences in assay length or differences in
growth rates between cells of interest. GR calculations are described in detail in Hafner
et al. 2016.
a. Calculate the average fluorescence of live cells from the replicates of untreated control wells at
the assay start (FL0,ctrl, see Table 5) (Table 12).
b. Calculate the average fluorescence of live cells from the replicates of the untreated control at
the timepoint of interest (FLt,ctrl, see Table 6). An example calculating the mean fluorescence
of live cells at 48 h is shown in Table 13.
Table 8. Lag exponential death (LED) fitted parameters
Camptothecin dose (mM) Rep. #
Lethal fraction
LFi LFp DO DR LFmaxLF0 . LF48
0 1 0.0573 . 0.0240 0.056 0.022 0.953 0.054 0.057*
0 2 0.0554 . 0.0249
0.01 1 0.0586 . 0.0275 0.057 0.028 11.374 0.133 0.059*
0.01 2 0.0564 . 0.0285
0.0316 1 0.0620 . 0.0274 0.061 0.030 1.841 0.060 0.062*
0.0316 2 0.0603 . 0.0341
0.1 1 0.0549 . 0.0456 0.048 0.046 34.480 0.014 0.056*
0.1 2 0.0542 . 0.0451
0.316 1 0.0583 . 0.0781 0.059 0.084 39.558 1.176 0.095*
0.316 2 0.0654 . 0.0857
1 1 0.0593 . 0.1998 0.060 0.219 14.586 0.081 0.252
1 2 0.0613 . 0.2518
3.16 1 0.0630 . 0.8295 0.061 1.000 13.239 0.041 0.856
3.16 2 0.0583 . 0.8559
10 1 0.0586 . 0.7943 0.061 0.957 14.547 0.056 0.891
10 2 0.0642 . 0.8911
ll
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c. Determine the fluorescence contributed by the proportion of the population that was still alive
at each timepoint in each of the treated conditions at the assay start (FL0,d) and any timepoint
of interest (FLt,d) (see Table 6).





2log 2ðFLMt;ctrl=FLM0;ctrlÞ  1
FL = modeled live cell fluorescence (from Table 6)
FLM = mean fluorescence of live cells (from Tables 12 and 13)
t = a given timepoint
x = a given drug concentration
a. Determine pharmacological parameters for GR values by curve fitting, using the same 4-
parameter logistic regression as for RV and FV, above in Quantification and statistical analysis
step 4b.
LIMITATIONS
The FLICK assay provides a single unified platform for evaluating drug response kinetics, as well as
determining a variety of pharmacological measures, such as relative viability, fractional viability,
and GR values. These values can be obtained at any time point in the assay window, or at the
assay end point. Additionally, because FLICK requires only one fluorescence channel to mark
dead cells, this assay can be optimized to be multiplexed with markers of other cell fates or re-
sponses. This protocol has been optimized for adherent cell lines, but should be easily adapted
to suspension cultures.
The FLICK assay has a few notable limitations. The use of a plate reader requires the user to manually
move plates between the incubator and the reader. The lack of automation may limit throughput,
although commercially available automated microscopes also generally accommodate only a small
number of plates. More critically, FLICK requires that the user select time points for analysis. As dis-
cussed in this protocol (Fluorescence measurements, step 14) and in the Troubleshooting section,
this may require some optimization depending on the kinetics of cell death observed for a given
drug. An additional limitation is that the output of this assay is not cell number, but fluorescence
values for a population of cells (i.e., a well of a plate). This value, however, is linearly proportional
Table 9. Lag exponential death (LED) fitted parameters, linear model (flat fit) included
Camptothecin dose (mM) Rep. #
Lethal fraction
LFi LFp DO DR LFmaxLF0 . LF48
0 1 0.0573 . 0.0240 0.034 0 48 0 0.057
0 2 0.0554 . 0.0249
0.01 1 0.0586 . 0.0275 0.037 0 48 0 0.059
0.01 2 0.0564 . 0.0285
0.0316 1 0.0620 . 0.0274 0.040 0 48 0 0.062
0.0316 2 0.0603 . 0.0341
0.1 1 0.0549 . 0.0456 0.048 0 48 0 0.056
0.1 2 0.0542 . 0.0451
0.316 1 0.0583 . 0.0781 0.067 0 48 0 0.095
0.316 2 0.0654 . 0.0857
1 1 0.0593 . 0.1998 0.060 0.219 14.586 0.081 0.252
1 2 0.0613 . 0.2518
3.16 1 0.0630 . 0.8295 0.061 1.000 13.239 0.041 0.856
3.16 2 0.0583 . 0.8559
10 1 0.0586 . 0.7943 0.061 0.957 14.547 0.056 0.891
10 2 0.0642 . 0.8911
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to the number of cells, so the number of cells can be estimated from fluorescence values by gener-
ating a standard curve, similar to the cell dilution used when calibrating SYTOX (see Before you
begin, step 1).
Some drugs emit fluorescence in the samewavelength as SYTOX and cannot be quantified using this
assay. In these situations, use of SYTOX variants that emit fluorescence in other wavelengths may be
helpful. This assay is also unable to measure the response to drugs that interfere with SYTOX fluo-
rescence or the ability of SYTOX to bind DNA. Lastly, the demarcation of dead cells by SYTOX re-
quires both plasma membrane rupture and disruption of the nuclear envelope. These membranes
require active maintenance, so SYTOXwill mark dead cells regardless of themechanism of cell death
caused by the drug. These events, however, do not occur with the same efficiency for all types of cell
death, which may affect the ability of SYTOX to accurately quantify dead cells.
Table 10. Fractional viability (FVt)
Camptothecin dose (mM) Rep. #
Fractional viability
FV0 FV16 FV20 FV24 FV40 FV44 FV48
0 1 0.9427 0.9623 0.9640 0.9682 0.9727 0.9749 0.9760
0.01 1 0.9414 0.9564 0.9621 0.9653 0.9713 0.9736 0.9725
0.0316 1 0.9380 0.9578 0.9608 0.9631 0.9684 0.9703 0.9726
0.1 1 0.9451 0.9515 0.9533 0.9557 0.9486 0.9444 0.9544
0.316 1 0.9417 0.9441 0.9438 0.9415 0.9316 0.9237 0.9219
1 1 0.9407 0.9234 0.8827 0.8378 0.8312 0.8132 0.8002
3.16 1 0.9370 0.8451 0.6849 0.5823 0.3920 0.2716 0.1705
10 1 0.9414 0.8835 0.7387 0.5797 0.3159 0.2712 0.2057
0 2 0.9446 0.9645 0.9663 0.9696 0.9749 0.9753 0.9751
0.01 2 0.9436 0.9557 0.9650 0.9672 0.9716 0.9712 0.9715
0.0316 2 0.9397 0.9558 0.9599 0.9610 0.9639 0.9655 0.9659
0.1 2 0.9458 0.9545 0.9545 0.9555 0.9572 0.9547 0.9549
0.316 2 0.9346 0.9423 0.9412 0.9431 0.9304 0.9055 0.9143
1 2 0.9387 0.9267 0.8866 0.8510 0.8159 0.7818 0.7482
3.16 2 0.9417 0.8573 0.7037 0.6044 0.3951 0.2655 0.1441
10 2 0.9358 0.8582 0.6940 0.5048 0.2711 0.1637 0.1089
Table 11. Relative viability (RVt)
Camptothecin dose (mM) Rep. #
Relative viability
RV0 RV16 RV20 RV24 RV40 RV44 RV48
0 1 0.9990 0.9694 0.9619 0.9550 0.9252 0.9188 0.9121
0.01 1 0.9977 0.9626 0.9591 0.9511 0.9221 0.9156 0.9067
0.0316 1 0.9940 0.9211 0.9046 0.8861 0.8202 0.8048 0.7908
0.1 1 1.0016 0.7979 0.7564 0.7160 0.5705 0.5375 0.5145
0.316 1 0.9979 0.7205 0.6656 0.6124 0.4426 0.4057 0.3745
1 1 0.9969 0.7196 0.6391 0.5624 0.4162 0.3783 0.3463
3.16 1 0.9930 0.5678 0.4119 0.3129 0.1355 0.0840 0.0473
10 1 0.9977 0.6126 0.4621 0.3265 0.1181 0.0915 0.0627
0 2 1.0010 1.0306 1.0381 1.0450 1.0748 1.0812 1.0879
0.01 2 1.0000 0.9688 0.9705 0.9631 0.9387 0.9312 0.9251
0.0316 2 0.9958 0.8834 0.8602 0.8332 0.7394 0.7182 0.6974
0.1 2 1.0023 0.7820 0.7357 0.6914 0.5432 0.5098 0.4802
0.316 2 0.9904 0.7038 0.6462 0.5939 0.4189 0.3748 0.3483
1 2 0.9948 0.7158 0.6348 0.5636 0.3996 0.3549 0.3152
3.16 2 0.9979 0.5797 0.4267 0.3280 0.1388 0.0836 0.0407
10 2 0.9917 0.5878 0.4276 0.2792 0.0983 0.0534 0.0320
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Our kinetic inference of live and dead cells over time makes one critical assumption regarding the
nature of growth for drug-treated populations. For any population growth that is observed over
time, our approach assumes that growth was exponential at a constant rate over time. While approx-
imately exponential growth is generally observed for healthy cells, the same is not necessarily true
for cells experiencing drug-induced stress. By simulating responses using a spectrum of different
growth models, we previously found that inferred response kinetics were stable regardless of which
growth model was chosen (e.g., linear, sigmoidal, and non-uniform over time) (Richards et al., 2020).
This overall robustness regardless of growth model depends on selection of a relatively short assay
time (48–72 h; generally 2–3 population doublings). At longer time points, solutions derived from
different growth assumptions will begin to diverge more substantially. In these situations, selection
of a population growth model that more accurately mimics what is observed for drug-induced
growth may be helpful.
Even at short assay times, our simulations did identify some situations that differ substantially from the
uniform exponential growth rate assumption; however, these required very peculiar growth kinetics
that were not ever observed experimentally. Furthermore, the kinetic data that result froman exponential
growth assumption correlate well with data derived from single cell microscopy for a panel of diverse
drugs. Nonetheless, in some situations the assumption of a constant exponential growth rate may pro-
duce incorrect inferences. Kinetic inference of total cells can become inaccurate for drugs that kill at very
fast rates and with early onset times. Drugs with these features compromise our calculation because the
cells havedecayed toomuchby the assay endpoint toproduce a SYTOX signal. These situations could be
remedied by ending the assay at an earlier time point.
TROUBLESHOOTING
Problem
Final pre-Triton measurement is higher than the post-Triton measurement (steps 14–16).
Potential solution
In principle, using Triton to lyse remaining viable cells should always lead to stable or increased SY-
TOX signal. If lethal fraction is  1, post-Triton measurements may be slightly lower or higher, just
due to measurement noise. A post-Triton SYTOX signal that is substantially decreased from the pre-
Triton measurement can result from agitating the plate and dislodging the dead cells which may
settle in a portion of the well in which fluorescence readings are not captured. This issue can be
remedied by allowing the dislodged cells to settle before reading the plate, or by repeating the
experiment being careful not to shake or agitate the plate.
Problem
Nonlinear relationship between cell number and SYTOX fluorescence (Before you begin, step 11).
Table 12. Untreated control at assay start (FL0,ctrl)
Camptothecin dose (mM) Replicate #
Live cell fluorescence
FL0,ctrl FLM0,ctrl
0 1 3,847 3,851
0 2 3,855
Table 13. Untreated control at timepoint of interest (FLt,ctrl)
Camptothecin dose (mM) Replicate #
Live cell fluorescence
FL48,ctrl FLM48,ctrl
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Potential solution
Assuming all signals are in the linear range (i.e., no readings of ‘‘INF,’’ ‘‘NaN,’’ ‘‘error,’’ etc.), non-
linearity can be caused by incomplete permeabilization. Visually inspect the plate to see if Triton
permeabilization has caused rupture of all cells. Alternatively, increase the Triton permeabilization
time.
Problem
Lethal fraction decreases over time (step 14).
Potential solution
Lethal fraction measurements generally increase over time until reaching a stable plateau. In rare
cases, LF% increases rapidly before slowly decreasing to a lower plateau. This can occur either
due to the emergence of a drug resistant clone or due to degradation of the SYTOX signal over
time. These two possibilities can be distinguished by directly measuring live cell kinetics over
time using the STACK assay (Forcina et al, 2017).
Problem
Inaccurate inference of death kinetics when comparing to other assays (Quantification and statistical
analysis, step 3).
Potential solution
In some situations, users may want to use kinetic data derived from this approach to parame-
terize dose/time selection for other experiments, for instance, finding time points before or after
the onset of cell death. These inferred times can be inaccurate if the population growth varies
significantly from the exponential growth model used. This is particularly an issue if growth in
drug-treated conditions has three characteristics: 1) very non-uniform growth over time, 2)
abrupt transition from growing to non-growing, and 3) transitions from growing to non-growing
are unrelated to the death onset time. In the absence of these three features, inferred kinetic
rates from this method should be accurate even if the population growth is non-exponential.
In rare situations where these issues occur, potential solutions are to: shorten the assay length
to minimize differences between varied growth assumptions, compute death kinetics using a
Table 14. GR values (GRt)
Camptothecin dose (mM) Rep. #
GR index
GR0 GR16 GR20 GR24 GR40 GR44 GR48
0 1 1 0.9148 0.9139 0.9145 0.9118 0.9124 0.9126
0.01 1 1 0.8992 0.9103 0.9093 0.9095 0.9102 0.9083
0.0316 1 1 0.7911 0.7922 0.7888 0.7862 0.7863 0.7873
0.1 1 1 0.4392 0.4424 0.4439 0.4364 0.4333 0.4417
0.316 1 1 0.2482 0.2482 0.2450 0.2399 0.2353 0.2356
1 1 1 0.2479 0.1920 0.1473 0.1966 0.1907 0.1894
3.16 1 1 0.1093 0.2818 0.3481 0.3802 0.4667 0.5521
10 1 1 0.0126 0.1835 0.3237 0.4298 0.4432 0.4867
0 2 1 1.0861 1.0864 1.0852 1.0854 1.0842 1.0835
0.01 2 1 0.9103 0.9315 0.9283 0.9270 0.9251 0.9249
0.0316 2 1 0.6817 0.6866 0.6821 0.6788 0.6790 0.6787
0.1 2 1 0.3964 0.3953 0.3947 0.3950 0.3927 0.3930
0.316 2 1 0.2198 0.2166 0.2174 0.2059 0.1890 0.1967
1 2 1 0.2420 0.1856 0.1521 0.1697 0.1520 0.1369
3.16 2 1 0.0886 0.2561 0.3210 0.3731 0.4694 0.5846
10 2 1 0.0618 0.2488 0.4157 0.4863 0.5813 0.6300
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different growth model, or use the STACK assay to directly observe death kinetics (Forcina,
et al. 2017).
Problem
Unreliable death onset time (Quantification and statistical analysis, step 3).
Potential solution
Selection of times to measure SYTOX fluorescence affects the accuracy of the death onset calcula-
tion. The inferred death onset time will vary substantially between experiments if it is not appropri-
ately constrained by death observed at the selected time points. A solution to this is to optimize the
selection of time points or to add more time points. The inference of death onset time will be
improved if death levels are sampled at3 consecutive time points, spaced 2–4 h apart, in the expo-
nentially increasing phase of death, and in the plateau phase of death.
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the Lead Contact, Michael Lee (michael.lee@umassmed.edu).
Materials availability
This protocol uses only materials and reagents that are commercially available.
Data and code availability
Sample datasets and code used for analyzing data using this protocol are available in a GitHub re-
positories (MJLee-Lab/fitGrowth; MJLee-Lab/fitLED; MJLee-Lab/fit_via).
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